Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q2 FY22 results · Jul–Sep 2021
Neuland Laboratories reported revenue from operations of ₹257.85 crore (up 6.8% from Q2 FY21) and net profit of ₹20.37 crore (down 5.0% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 257.85 | 241.39 | +6.8% | 200.89 | +28.4% |
| Other income | 0.29 | 0.61 | −52.7% | 2.06 | −86.1% |
| Total income | 258.13 | 242.00 | +6.7% | 202.94 | +27.2% |
| Profit before tax | 27.58 | 28.69 | −3.9% | 12.07 | +128.4% |
| Net profit for the period | 20.37 | 21.44 | −5.0% | 8.73 | +133.2% |
| EPS, basic (₹) | 15.88 | 16.71 | −5.0% | 6.81 | +133.2% |
| Net margin (%) | 7.9 | 8.9 | 4.3 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 257.85 | 241.39 | +6.8% | 200.89 | +28.4% |
| Other income | 0.29 | 0.61 | −52.7% | 2.06 | −86.1% |
| Total income | 258.13 | 242.00 | +6.7% | 202.94 | +27.2% |
| Profit before tax | 27.53 | 28.58 | −3.7% | 11.99 | +129.7% |
| Net profit for the period | 20.33 | 21.34 | −4.7% | 8.65 | +135.1% |
| EPS, basic (₹) | 15.84 | 16.63 | −4.8% | 6.74 | +135.0% |
| Net margin (%) | 7.9 | 8.8 | 4.3 |
Consolidated
- Filed with BSE
- 29 Oct 2021, 16:09 IST
- Board meeting
- 29 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Oct 2021, 16:09 IST
- Board meeting
- 29 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE